Endovia Health Sciences annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Endovia Health Sciences Stock-Based Compensation Growth & History (EDVA)
Endovia Health Sciences's stock-based compensation was $8.6M for fiscal 2025.
View full Endovia Health Sciences company overviewEndovia Health Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.6M | $6.3M | +265.92% |
| 2024 | 2024-12-31 | $2.4M | $1.2M | +101.45% |
| 2023 | 2023-12-31 | $1.2M | −$6.2M | −84.21% |
| 2022 | 2022-12-31 | $7.4M | $3.4M | +86.56% |
| 2021 | 2021-12-31 | $4.0M | $1.6M | +70.52% |
| 2020 | 2020-12-31 | $2.3M | $709,188 | +43.77% |
| 2019 | 2019-12-31 | $1.6M | $1.6M | — |
| 2018 | 2018-12-31 | $0 | — | — |
Endovia Health Sciences quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | $1.1M | +1956.40% |
| Q1 2026 | 2026-03-31 | $176,972 | $41,263 | +30.41% |
| Q4 2025 | 2025-12-31 | $682,381 | $411,368 | +151.79% |
| Q3 2025 | 2025-09-30 | $7.8M | $7.6M | +4052.30% |
| Q2 2025 | 2025-06-30 | $53,859 | −$1.3M | −95.99% |
| Q1 2025 | 2025-03-31 | $135,709 | −$420,963 | −75.62% |
| Q4 2024 | 2024-12-31 | $271,013 | — | — |
| Q3 2024 | 2024-09-30 | $186,682 | −$180,562 | −49.17% |
| Q2 2024 | 2024-06-30 | $1.3M | $701,220 | +109.38% |
| Q1 2024 | 2024-03-31 | $556,672 | $340,912 | +158.01% |
| Q3 2023 | 2023-09-30 | $367,244 | −$1.3M | −78.36% |
| Q2 2023 | 2023-06-30 | $641,097 | −$2.1M | −76.88% |
| Q1 2023 | 2023-03-31 | $215,760 | −$2.1M | −90.84% |
| Q4 2022 | 2022-12-31 | $584,772 | — | — |
| Q3 2022 | 2022-09-30 | $1.7M | −$7.1M | −80.78% |
| Q2 2022 | 2022-06-30 | $2.8M | $1.4M | +102.37% |
| Q1 2022 | 2022-03-31 | $2.4M | $1.6M | +222.22% |
| Q3 2021 | 2021-09-30 | $8.8M | $7.1M | +410.51% |
| Q2 2021 | 2021-06-30 | $1.4M | $1.4M | — |
| Q1 2021 | 2021-03-31 | $731,035 | $131,035 | +21.84% |
| Q4 2020 | 2020-12-31 | $0 | — | — |
| Q3 2020 | 2020-09-30 | $1.7M | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $600,000 | — | — |
Endovia Health Sciences stock-based compensation trends
Over the last five fiscal years, Endovia Health Sciences's stock-based compensation increased from $2.3M to $8.6M, a change of $6.3M. The latest reported quarter, Q2 2026, shows $1.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endovia Health Sciences source filings ↗